Blueprint Medicines Net Worth
Blueprint Medicines Net Worth Breakdown | BPMC |
Blueprint Medicines Net Worth Analysis
Blueprint Medicines' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Blueprint Medicines' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Blueprint Medicines' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Blueprint Medicines' net worth analysis. One common approach is to calculate Blueprint Medicines' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Blueprint Medicines' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Blueprint Medicines' net worth. This approach calculates the present value of Blueprint Medicines' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Blueprint Medicines' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Blueprint Medicines' net worth. This involves comparing Blueprint Medicines' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Blueprint Medicines' net worth relative to its peers.
Enterprise Value |
|
To determine if Blueprint Medicines is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Blueprint Medicines' net worth research are outlined below:
| Blueprint Medicines had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 508.82 M. Net Loss for the year was (67.09 M) with profit before overhead, payroll, taxes, and interest of 488.66 M. | |
| Blueprint Medicines Corp currently holds about 853.11 M in cash with (192.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28. | |
| Blueprint Medicines has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thefly.com: Blueprint Medicines initiated with bullish view at Jefferies, heres why BPMC |
Blueprint Medicines uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Blueprint Medicines Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Blueprint Medicines' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Blueprint Medicines Target Price Consensus
Blueprint target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Blueprint Medicines' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 20 | Strong Buy |
Most Blueprint analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Blueprint stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Blueprint Medicines Corp, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBlueprint Medicines Target Price Projection
Blueprint Medicines' current and average target prices are 88.47 and 125.58, respectively. The current price of Blueprint Medicines is the price at which Blueprint Medicines Corp is currently trading. On the other hand, Blueprint Medicines' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Blueprint Medicines Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Blueprint Medicines Target Price
Know Blueprint Medicines' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Blueprint Medicines is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Blueprint Medicines Corp backward and forwards among themselves. Blueprint Medicines' institutional investor refers to the entity that pools money to purchase Blueprint Medicines' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Jpmorgan Chase & Co | 2024-12-31 | 1.2 M | |
| Alliancebernstein L.p. | 2024-12-31 | 1.1 M | |
| Rock Springs Capital Management Lp | 2024-12-31 | 1.1 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 1 M | |
| Amvescap Plc. | 2024-12-31 | 960.4 K | |
| Hood River Capital Management Llc | 2024-12-31 | 879.9 K | |
| Eventide Asset Management, Llc | 2024-12-31 | 862.3 K | |
| American Century Companies Inc | 2024-12-31 | 839.2 K | |
| Alkeon Capital Management, Llc | 2024-12-31 | 800.6 K | |
| Blackrock Inc | 2024-12-31 | 6.9 M | |
| Vanguard Group Inc | 2024-12-31 | 6.8 M |
Follow Blueprint Medicines' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.78 B.Market Cap |
|
Project Blueprint Medicines' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.06) | (0.06) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.06) | (0.06) | |
| Return On Equity | (0.22) | (0.21) |
When accessing Blueprint Medicines' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Blueprint Medicines' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Blueprint Medicines' profitability and make more informed investment decisions.
Please note, the presentation of Blueprint Medicines' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Blueprint Medicines' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Blueprint Medicines' management manipulating its earnings.
Evaluate Blueprint Medicines' management efficiency
Blueprint Medicines Corp has return on total asset (ROA) of (0.1189) % which means that it has lost $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3126) %, meaning that it created substantial loss on money invested by shareholders. Blueprint Medicines' management efficiency ratios could be used to measure how well Blueprint Medicines manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to -0.06. In addition to that, Return On Capital Employed is expected to decline to -0.24. At present, Blueprint Medicines' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 613.2 M, whereas Total Assets are forecasted to decline to about 827.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.75 | 7.54 | |
| Tangible Book Value Per Share | 4.75 | 7.54 | |
| Enterprise Value Over EBITDA | (25.97) | (24.67) | |
| Price Book Value Ratio | 18.36 | 19.27 | |
| Enterprise Value Multiple | (25.97) | (24.67) | |
| Price Fair Value | 18.36 | 19.27 | |
| Enterprise Value | 2 B | 2.1 B |
Blueprint Medicines Corp has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Enterprise Value Revenue 11.0762 | Revenue | Quarterly Revenue Growth 1.034 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Blueprint Medicines insiders, such as employees or executives, is commonly permitted as long as it does not rely on Blueprint Medicines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Blueprint Medicines insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Blueprint Medicines Corporate Filings
F4 | 17th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Blueprint Medicines Earnings Estimation Breakdown
The calculation of Blueprint Medicines' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Blueprint Medicines is estimated to be -1.66 with the future projection ranging from a low of -0.9 to a high of 0.4773. Please be aware that this consensus of annual earnings estimates for Blueprint Medicines Corp is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.9 Lowest | Expected EPS | 0.48 Highest |
Blueprint Medicines Earnings Projection Consensus
Suppose the current estimates of Blueprint Medicines' value are higher than the current market price of the Blueprint Medicines stock. In this case, investors may conclude that Blueprint Medicines is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Blueprint Medicines' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 22 | 80.16% | -0.79 | -1.66 | -1.07 |
Blueprint Medicines Earnings per Share Projection vs Actual
Actual Earning per Share of Blueprint Medicines refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Blueprint Medicines Corp predict the company's earnings will be in the future. The higher the earnings per share of Blueprint Medicines, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Blueprint Medicines Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Blueprint Medicines, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Blueprint Medicines should always be considered in relation to other companies to make a more educated investment decision.Blueprint Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Blueprint Medicines' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-13 | 2024-12-31 | -0.7141 | -0.79 | -0.0759 | 10 | ||
2024-10-30 | 2024-09-30 | -0.97 | -0.89 | 0.08 | 8 | ||
2024-08-01 | 2024-06-30 | -1.29 | -0.8 | 0.49 | 37 | ||
2024-05-02 | 2024-03-31 | -1.66 | 1.4 | 3.06 | 184 | ||
2024-02-15 | 2023-12-31 | -2.04 | -1.82 | 0.22 | 10 | ||
2023-10-26 | 2023-09-30 | -2.37 | -2.2 | 0.17 | 7 | ||
2023-08-02 | 2023-06-30 | -2.54 | -2.19 | 0.35 | 13 | ||
2023-05-04 | 2023-03-31 | -2.67 | -2.15 | 0.52 | 19 | ||
2023-02-16 | 2022-12-31 | -2.65 | -2.65 | 0.0 | 0 | ||
2022-11-01 | 2022-09-30 | -2.49 | -2.23 | 0.26 | 10 | ||
2022-08-02 | 2022-06-30 | -2.23 | -2.68 | -0.45 | 20 | ||
2022-05-03 | 2022-03-31 | -1.86 | -1.79 | 0.07 | 3 | ||
2022-02-16 | 2021-12-31 | -1.65 | -5.4 | -3.75 | 227 | ||
2021-10-28 | 2021-09-30 | -1.63 | -1.94 | -0.31 | 19 | ||
2021-07-29 | 2021-06-30 | -1.86 | -1.86 | 0.0 | 0 | ||
2021-04-29 | 2021-03-31 | -1.87 | -1.72 | 0.15 | 8 | ||
2021-02-17 | 2020-12-31 | -1.62 | -1.53 | 0.09 | 5 | ||
2020-10-29 | 2020-09-30 | 7.72 | 11.16 | 3.44 | 44 | ||
2020-07-30 | 2020-06-30 | -2.14 | -2.28 | -0.14 | 6 | ||
2020-05-06 | 2020-03-31 | -2.08 | -2.11 | -0.03 | 1 | ||
2020-02-13 | 2019-12-31 | -1.69 | -1.35 | 0.34 | 20 | ||
2019-11-05 | 2019-09-30 | -2.18 | -1.93 | 0.25 | 11 | ||
2019-08-01 | 2019-06-30 | -1.91 | -2.04 | -0.13 | 6 | ||
2019-05-09 | 2019-03-31 | -1.86 | -1.98 | -0.12 | 6 | ||
2019-02-26 | 2018-12-31 | -1.76 | -1.83 | -0.07 | 3 | ||
2018-10-30 | 2018-09-30 | -1.51 | -1.66 | -0.15 | 9 | ||
2018-08-01 | 2018-06-30 | -1.32 | -0.62 | 0.7 | 53 | ||
2018-05-02 | 2018-03-31 | -1.13 | -1.29 | -0.16 | 14 | ||
2018-02-21 | 2017-12-31 | -1.11 | -1.23 | -0.12 | 10 | ||
2017-10-31 | 2017-09-30 | -0.91 | -0.96 | -0.05 | 5 | ||
2017-08-02 | 2017-06-30 | -0.79 | -0.86 | -0.07 | 8 | ||
2017-05-03 | 2017-03-31 | -0.76 | -0.84 | -0.08 | 10 | ||
2017-03-09 | 2016-12-31 | -0.76 | -0.75 | 0.01 | 1 | ||
2016-11-10 | 2016-09-30 | -0.79 | -0.62 | 0.17 | 21 | ||
2016-08-09 | 2016-06-30 | -0.73 | -0.7 | 0.03 | 4 | ||
2016-05-10 | 2016-03-31 | -0.69 | -0.57 | 0.12 | 17 | ||
2016-03-11 | 2015-12-31 | -0.52 | -0.58 | -0.06 | 11 | ||
2015-11-09 | 2015-09-30 | -0.53 | -0.47 | 0.06 | 11 | ||
2015-08-10 | 2015-06-30 | -0.52 | -0.68 | -0.16 | 30 | ||
2015-06-11 | 2015-03-31 | -2.11 | -8.23 | -6.12 | 290 |
Blueprint Medicines Corporate Management
| Dr MBA | Chief Officer | Profile | |
| Ariel Hurley | Principal Accounting Officer | Profile | |
| Tracey Esq | Chief VP | Profile | |
| Christina Rossi | Chief Commercial Officer | Profile | |
| Michael CPA | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.07) | Revenue Per Share | Quarterly Revenue Growth 1.034 | Return On Assets | Return On Equity |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.